Neurology

Biologics

Questions discussed in this category

Would you stop belimumab in a patient with SLE starting ravulizumab (C5 inhibitor) for myasthenia gravis due to concern for additive immunosuppression?

3 Answers available

What would be the main indications for opting for biosimilars over an original biologic, outside of insurance barriers?

Are there any instances where you would prefer a biosimilar rather than the reference product?

2 Answers available

Papers discussed in this category

Front Immunol, 2021 Jul 14

Complement C4, Infections, and Autoimmune Diseases.

Arthritis & rheumatology (Hoboken, N.J.), 2018-03

The Science Behind Biosimilars: Entering a New Era of Biologic Therapy.

Related Topics in Neurology